Exits, 10/30/2026

How we did on the trades we exited this week.

Oct 31, 2026

Our year-to-date trade performance through October 30th appears below.

2026 YTD: 280 fully exited trades through October 30, 2026; win rate 49.6%; average return on original maximum risk +20.8%; average duration 143 calendar days; average winner +109.2%; average loser -66.3%; illustrative simple annualized return +53.0%, assuming continuously deployed equal-risk capital. Latest actual completed exit October 28. Before fees.

This Week’s Trade Exits

As soon as I exit a trade, I note that in the comments of the post where I first mentioned the trade; at the end of the week, I try to track them all in one post. Starting in July, 2024, I have also been tracking them in a spreadsheet. These are the trades I exited this week.

Clicking on one of the exit cards should take you to the original alert where we mentioned the trade; exits will be documented in the comments on the dates they occurred.

Stocks or Exchange Traded Products

None

Options

1. Long Call On Viasat (VSAT). Partial Exit. −31.0% PREMIUM RETURN. Bought one December 18, 2026 $75 call for $10.00 on 6/25/2026. Sold it for $6.90 on 10/27/2026. 124 calendar days. Signal: PA Top Names. Before fees.

2. Put Spread On Genmab (GMAB). Partial Exit. −11.4% RETURN ON MAX RISK. Entered the February 19, 2027 $30/$25 put spread on 9/10/2026 at a broker-allocated $0.42 net debit. Exited it for a $0.20 net debit on 10/28/2026. Loss: $62 on $542 of component maximum risk. 48 calendar days. Signal: Multibaggers. Before fees.

3. 4-Leg Hybrid Combo On SLB (SLB). Full Exit. +23.3% RETURN ON MAX RISK. Entered on 6/3/2026 at a $1.00 net debit. Bought back the short call for $0.20 on 6/18; sold the long call for $2.80 on 8/31. Exited the put spread for a $0.20 net debit on 10/27/2026. Net closing proceeds: $2.40. 140.0% return on net outlay. 146 calendar days. Signal: PA Top Names. Before fees.

4. Short Call On Bicara Therapeutics (BCAX). Partial Exit. +89.9% PREMIUM RETURN. Sold one March 19, 2027 $40 call for $1.98 on 8/11/2026. Bought it back for $0.20 on 10/28/2026. 78 calendar days. Signal: Multibaggers. Before fees.

5. Call Diagonal On AXT (AXTI). Full Exit. +95.2% RETURN ON MAX RISK. Entered on 10/26/2026 at a net debit of $2.10. Exited the three-contract November 6 $57 / October 30 $62 call diagonal on 10/28/2026 at a net credit of $4.10. 2 calendar days. Signal: Multibaggers. Before fees.

6. Long Call On Genmab (GMAB). Partial Exit. +744.6% PREMIUM RETURN. Bought one February 19, 2027 $40 call for $2.22 on 9/10/2026. Sold it for $18.75 on 10/28/2026. 48 calendar days. Signal: Multibaggers. Before fees.

Comments

Stocks or Exchange-Traded Products

We didn’t have any stock or ETF exits this week, but our Top Names’ performance remains strong: the April 30, 2026 cohort averaged 41.72% over six months, versus 4.85% for SPY.

Portfolio Armor Top Names: April 30, 2026 cohort; six-month unhedged average 41.72% versus SPY 4.85%, with the original plot and all ten stock returns. — *Screen capture via the Portfolio Armor iPhone app.*

Options

AXT turned a two-day holding period into a 95% return on maximum risk. Exiting prior to earnings proved to be prudent.

Bicara Therapeutics fell sharply after the same head-and-neck cancer readout that lifted Genmab; that drop enabled us to buy-to-close our short call on it, collecting about 90% of its premium.

Genmab shows why we sometimes buy more calls than we sell. We sold the unmatched February call for a 745% gain on its premium, while keeping one February long call against the January short call. That locked in the extra call’s gain and preserved the remaining calendar’s coverage.